Radiation oncologist Jedidiah Monson has been appointed to the position of chief medical officer at Beyond Cancer Ltd, an exempted company registered in Bermuda.

Beyond Cancer, an affiliate of Beyond Air Inc, is focused on developing ultra-high concentration nitric oxide for the treatment of solid tumours.

Selena Chaisson, CEO of Beyond Cancer, said: “We are excited to appoint Dr Monson as our chief medical officer at this important point in the short history of Beyond Cancer.

“In this role, he will oversee our first-in-human trial in Israel, which is expected to begin by mid-2022, as well as spearhead our efforts to begin clinical trials in the US.”

She added: “Dr Monson’s contributions to the field of oncology and to patients at a prestigious clinical care and research focused institution will be an invaluable resource for Beyond Cancer as we continue our mission of bringing ultra-high concentration nitric oxide therapy to solid tumour patients.”

Dr Monson said: “The concept of nitric oxide utilised at ultra-high concentrations to impart an immune response with potentially minimal side effects is an exciting prospect.

“The preclinical data presented by Beyond Cancer to date have shown UNO therapy has the potential to be a very important treatment option for cancer patients and their caregivers.

“I am excited to join Beyond Cancer as we look to begin enrolling patients in a first-in-human clinical trial.”

The company said Dr Monson was a board-certified radiation oncologist and brought more than 25 years of clinical oncology experience to Beyond Cancer.

Dr Monson, a founding partner of California Cancer Associates for Research & Excellence (cCARE) in 2008, oversaw its growth into the largest private practice oncology group in the state of California with a focus on research and excellence in clinical care.

In April, cCARE merged with Integrated Oncology Network resulting in a nationwide oncology and healthcare management group, with a presence in 57 oncology centres across 14 states.

Dr Monson is a member of the American College of Radiology and the American Society of Therapeutic Radiology & Oncology.

He earned his MD from Stanford University School of Medicine and completed his radiation oncology residency at the Joint Centre for Radiation Therapy at Harvard Medical School.

During his residency, Dr Monson received an MPH from Harvard School of Public Health.